PCOS Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in women of reproductive age, affecting 8–13% of women globally (representing approximately 116 million women), and the leading cause of anovulatory infertility. It is characterised by a combination of three features, two of which are required for diagnosis under the Rotterdam criteria: oligo- or anovulation (irregular or absent periods, occurring more than 35 days apart or fewer than 8 per year); clinical or biochemical evidence of androgen excess (hirsutism — excessive male-pattern hair growth; acne; alopecia; or elevated serum androgens — testosterone, DHEAS, or free androgen index); and polycystic ovarian morphology on ultrasound (12 or more follicles in one ovary, or ovarian volume above 10 mL). The syndrome is heterogeneous — not all women have all three features, and PCOS phenotype varies from the predominantly hyperandrogenic to the predominantly reproductive to the predominantly metabolic.

The underlying pathophysiology involves excessive gonadotrophin-releasing hormone (GnRH) pulsatility increasing the LH:FSH ratio, which stimulates excess androgen production by theca cells; relative FSH deficiency impairs follicular maturation and prevents ovulation. Insulin resistance — present in 50–70% of women with PCOS regardless of body weight — exacerbates androgen excess by stimulating ovarian androgen production directly and by reducing sex hormone-binding globulin (SHBG), increasing free androgen bioavailability. Chronic anovulation results in continuous unopposed oestrogen stimulation of the endometrium, increasing the long-term risk of endometrial hyperplasia and carcinoma.

Diagnosis requires exclusion of other causes of hyperandrogenism and anovulation — thyroid disease (hypothyroidism), hyperprolactinaemia, congenital adrenal hyperplasia (21-hydroxylase deficiency), Cushing's syndrome, and androgen-secreting tumours must be excluded biochemically. Treatment of PCOS is symptom-directed and does not cure the underlying disorder, which typically persists through the reproductive years — though many features improve with the hormonal changes of perimenopause.

PCOS treatment addresses four main clinical domains: menstrual irregularity and reproductive health, hyperandrogenism symptoms, fertility, and metabolic and long-term health. Menstrual irregularity — oligomenorrhoea or amenorrhoea — causes psychological distress, unpredictable bleeding, and the long-term risk of endometrial hyperplasia from unopposed oestrogen. Hormonal treatment to induce regular withdrawal bleeds (at least every 3 months) is recommended to protect the endometrium. Hyperandrogenism causes hirsutism (scoring with the modified Ferriman-Gallwey scale), acne, and scalp hair thinning, with significant psychological impact and reduced quality of life.

Anovulatory infertility is a defining clinical consequence — women with PCOS who wish to conceive require ovulation induction. Long-term metabolic risks associated with PCOS include insulin resistance, impaired fasting glucose, Type 2 diabetes (lifetime risk 3–7 fold higher than the general population), metabolic syndrome, dyslipidaemia, non-alcoholic fatty liver disease, hypertension, and an increased risk of cardiovascular disease. Obese women with PCOS are at particularly high metabolic risk, and weight loss of even 5–10% can significantly restore ovulation, improve androgen levels, and reduce insulin resistance. Psychological morbidity — anxiety, depression, eating disorders, and reduced health-related quality of life — affects approximately 30–40% of women with PCOS and deserves explicit assessment and management.

All women diagnosed with PCOS are candidates for lifestyle-based interventions (weight management, exercise, healthy diet) regardless of symptom severity, BMI, or fertility intentions — these provide the widest range of benefits across all PCOS features with no contraindications. Pharmacological treatment is tailored to the woman's primary clinical concerns and reproductive intentions.

Combined oral contraceptive pill (COCP) is appropriate for women not seeking pregnancy who require menstrual regulation and/or hyperandrogenism management, in the absence of cardiovascular risk factors, history of venous thromboembolism, migraine with aura, active liver disease, or oestrogen-sensitive cancer — standard COCP contraindications apply. Metformin is appropriate for women with insulin resistance, impaired glucose tolerance, or Type 2 diabetes, and as adjunct to lifestyle for weight management and menstrual regularity. Ovulation induction with letrozole or clomiphene is appropriate for women with anovulatory infertility who wish to conceive and have no contraindication to ovulation induction, with assessment of tubal patency and semen analysis before initiation.

Lifestyle modification — caloric restriction targeting 5–10% weight loss in overweight and obese women with PCOS — is the most effective and fundamental first-line treatment. A 5% weight loss is sufficient to restore ovulation in approximately 30% of anovulatory overweight women with PCOS, improve insulin sensitivity, and reduce androgen levels. Exercise, both aerobic and resistance training, independently improves insulin sensitivity and reduces testosterone levels. The ESHRE/ASRM 2023 International Evidence-Based Guideline on PCOS strongly endorses lifestyle interventions as first-line therapy for all manifestations of PCOS.

The combined oral contraceptive pill (COCP) is the pharmacological cornerstone of PCOS management for women not seeking pregnancy. It suppresses LH and reduces ovarian androgen production, while the oestrogen component increases SHBG, reducing free testosterone. Any COCP provides endometrial protection and menstrual regulation, but anti-androgenic progestogens (drospirenone, cyproterone acetate, chlormadinone) may provide additional benefit for hirsutism and acne. Spironolactone (an anti-androgen) added to or substituted for the COCP is used for refractory hirsutism. Metformin (a biguanide insulin sensitiser) — the cornerstone of Type 2 diabetes treatment — is used in PCOS to improve insulin resistance, restore menstrual regularity (in approximately 40–50% of treated patients), reduce testosterone levels, and aid weight management. For ovulation induction, letrozole (an aromatase inhibitor) has superseded clomiphene citrate as first-line based on superior ovulation and live birth rates; it is given orally for 5 days in the early follicular phase. Gonadotrophin injections (FSH) are second-line for ovulation induction when oral agents fail, with careful monitoring for ovarian hyperstimulation syndrome (OHSS). IVF is reserved for cases where other ovulation induction has failed.

Lifestyle interventions achieve menstrual cycle regularisation in 30–50% of overweight/obese women with PCOS, with restoration of ovulation and spontaneous conception in a significant proportion. Even without achieving target weight loss, structured exercise programmes improve insulin sensitivity, androgen levels, and psychological wellbeing in women with PCOS. Combined oral contraceptive pill use for 12 months achieves meaningful improvement in hirsutism (measured by modified Ferriman-Gallwey score) in the majority of women, reduces acne, and provides effective contraception and endometrial protection.

Letrozole-based ovulation induction achieves ovulation rates of 60–80% per cycle and cumulative live birth rates of 65–70% after six treatment cycles — substantially better than clomiphene (cumulative live birth 45–50%) in the landmark NICHD Reproductive Medicine Network trial (Legro et al., NEJM 2014). Metformin reduces the risk of progression from impaired glucose tolerance to Type 2 diabetes in women with PCOS by approximately 30–40%, comparable to lifestyle intervention and superior to placebo. Long-term COCP use provides endometrial cancer prevention in women with chronic anovulation and unopposed oestrogen exposure.

Combined oral contraceptive pills carry the standard COCP risks: small increased risk of venous thromboembolism (VTE) — approximately 3–4 fold above the baseline population risk, but still low in absolute terms in healthy young women; small increased risk of ischaemic stroke and myocardial infarction in women with additional cardiovascular risk factors (smoking, hypertension, migraine with aura, obesity); and a marginally increased risk of cervical cancer with prolonged use. The cardiovascular risk of COCP must be balanced against the background metabolic risks of PCOS itself, including insulin resistance and dyslipidaemia.

Ovulation induction with gonadotrophins carries a 5–10% risk of multiple pregnancy (twins or higher-order multiples) if cycle monitoring and cancellation protocols are not rigorously followed, and a risk of ovarian hyperstimulation syndrome (OHSS) — a potentially life-threatening complication of excessive ovarian response with fluid shifts, ascites, and thromboembolism. GnRH antagonist protocols and trigger agent modification reduce but do not eliminate OHSS risk. Metformin commonly causes gastrointestinal side effects (nausea, diarrhoea, flatulence) at initiation, which usually resolve within 2–4 weeks and are minimised by starting at low doses with gradual titration. Anti-androgens such as spironolactone are teratogenic and require reliable contraception use.

Women with PCOS require long-term follow-up given the chronic nature of the syndrome and its metabolic implications. Annual review should include: blood pressure, BMI and waist circumference, fasting glucose and lipid profile (metabolic syndrome screening), menstrual pattern assessment, and psychological wellbeing evaluation. Women with impaired fasting glucose at diagnosis should undergo annual oral glucose tolerance test to detect progression to Type 2 diabetes.

Women with PCOS who are not taking hormonal contraception and have oligomenorrhoea should undergo endometrial ultrasound every 1–2 years; endometrial thickness above 7–10 mm or any endometrial irregularity warrants endometrial biopsy to exclude hyperplasia. For women seeking conception, ovulation tracking (urinary LH kit, cycle day 21 serum progesterone) documents ovulatory cycles before embarking on ovulation induction. After successful pregnancy with PCOS, gestational diabetes screening at 24–28 weeks is recommended due to the significantly elevated risk. Women with PCOS in mid-life should be reassessed for evolving metabolic risk as insulin resistance tends to worsen with age and menopausal adiposity redistribution.

Lifestyle interventions for PCOS — dietary counselling, exercise programmes — carry minimal direct medical cost, though structured behavioural weight management programmes may cost $200–1,000 in the US. Combined oral contraceptives cost $5–50 per month; metformin generic is under $5 per month globally and widely available. Letrozole and clomiphene for ovulation induction are inexpensive ($10–50 per treatment cycle). Ovulation induction with gonadotrophin injections (FSH ampoules) costs $500–3,000 per cycle in the US including monitoring; IVF for PCOS-related infertility adds costs of $12,000–20,000 per cycle in the US.

For women seeking fertility treatment abroad, significant cost savings are available. Gonadotrophin ovulation induction monitoring and treatment at major fertility clinics in India costs $300–800 per cycle; IVF for PCOS in India costs $2,500–5,000 per cycle at internationally accredited fertility centres — 75–80% less than US pricing. Thailand and Spain are also established destinations for affordable fertility treatment with high success rates. Polycystic ovary syndrome specialist consultations, DEXA scanning for metabolic assessment, and androgen blood tests are available throughout South and Southeast Asia at $20–80 per consultation, compared to $200–500 in the US.

Inositols — particularly myo-inositol and D-chiro-inositol, available as dietary supplements — have emerging evidence supporting improvement in insulin sensitivity, androgen levels, and menstrual regularity in PCOS, with a favourable safety profile. The ESHRE/ASRM 2023 PCOS guideline acknowledges inositol as a potential adjunct treatment though notes that current evidence quality is low-to-moderate and standardised preparations are lacking. Myo-inositol at a dose of 2–4 g daily combined with folic acid is the most studied preparation.

Laparoscopic ovarian drilling (LOD) — a surgical technique in which diathermy or laser punctures are applied to the ovarian surface to destroy androgen-producing theca cells — is a second-line surgical option for anovulatory PCOS women resistant to oral ovulation induction agents, offered as an alternative to gonadotrophin injections. LOD achieves cumulative pregnancy rates equivalent to gonadotrophin treatment over 6–12 months without the multiple pregnancy and OHSS risks, and can restore ovulation for 12–18 months after a single procedure. Acupuncture has limited evidence for modest improvement in PCOS-related menstrual irregularity in small trials, but current evidence is insufficient to recommend as a standard treatment.